Published by: Kowsar

Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population

Zahra Tolou-Ghamari 1 , *
Author Information
1 Isfahan Neurosciences Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Thrita: September 01, 2015, 4 (3); e28644
  • Published Online: September 6, 2015
  • Article Type: Research Article
  • Received: March 14, 2015
  • Revised: April 26, 2015
  • Accepted: May 17, 2015
  • DOI: 10.5812/thrita.28644

To Cite: Tolou-Ghamari Z. Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population, Thrita. 2015 ;4(3):e28644. doi: 10.5812/thrita.28644.

Copyright © 2015, Thrita. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009; 78(9): 1083-94[DOI][PubMed]
  • 2. Burns SA, Lee Archer R, Chavis JA, Tull CA, Hensley LL, Drew PD. Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Brain Res. 2012; 1473: 236-41[DOI][PubMed]
  • 3. Rommer PS, Stuve O. Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. Curr Treat Options Neurol. 2013; 15(3): 241-58[DOI][PubMed]
  • 4. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013; 5[DOI][PubMed]
  • 5. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: why? When? How? CNS Drugs. 2013; 27(6): 403-9[DOI][PubMed]
  • 6. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004; 18(6): 379-96[PubMed]
  • 7. Chan A, Lo-Coco F. Mitoxantrone-related acute leukemia in MS: an open or closed book? Neurology. 2013; 80(16): 1529-33[DOI][PubMed]
  • 8. Hofmann A, Stellmann JP, Kasper J, Ufer F, Elias WG, Pauly I, et al. Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients. Mult Scler. 2013; 19(7): 920-5[DOI][PubMed]
  • 9. Lee CK, Gebski VJ, Coates AS, Veillard AS, Harvey V, Tattersall MH, et al. Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. Springerplus. 2013; 2: 391[DOI][PubMed]
  • 10. Durrieu G, Mazau B, Jegu J, Lapeyre-Mestre M, Delord JP, Montastruc JL, et al. Drugs and cancer: an analysis of the French Pharmacovigilance Database. Therapie. 2013; 68(3): 149-54[DOI][PubMed]
  • 11. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick AD, Dahlgren L, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013; 13(3): 251-60[DOI][PubMed]
  • 12. Rossato LG, Costa VM, Dallegrave E, Arbo M, Dinis-Oliveira RJ, Santos-Silva A, et al. Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. Basic Clin Pharmacol Toxicol. 2014; 114(3): 254-62[DOI][PubMed]
  • 13. Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol. 2014; 175(3): 397-407[DOI][PubMed]
  • 14. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013; 6[DOI][PubMed]
  • 15. Hamzehloo A, Etemadifar M. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Arch Iran Med. 2007; 10(1): 59-64[PubMed]
  • 16. Hamzehloo A, Etemadifar M. Early onset cardiotoxicity associated with mitoxantrone in patients with multiple sclerosis. Neurosciences (Riyadh). 2006; 11(3): 221-2[PubMed]
  • 17. An G, Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. AAPS J. 2012; 14(2): 352-64[DOI][PubMed]
  • 18. Patel KJ, Tredan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol. 2013; 72(1): 127-38[DOI][PubMed]
  • 19. Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital. Int J Prev Med. 2013; 4-8[PubMed]
  • 20. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in patients. Cancer Treat Rev. 1983; 10 Suppl B: 23-7[DOI][PubMed]
  • 21. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs. 1985; 3(2): 109-16[PubMed]
  • 22. Tolou Ghamari Z, Mehavari Habibabadi J, Palizban AA. Evidence-Based Pharmacotherapy of Epilepsy. Arch Neurosci. 2014; 2(2)[DOI]
  • 23. Shaygannejad V, Tolou-Ghamari Z. What is the Real Fate of Vitamin D in Multiple Sclerosis? Int J Prev Med. 2013; 4-64[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments